Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: Understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations

Pharmaceutical Research

Volumn 30, Issue 12, 2013, Pages 3059-3076

  Williams, Hywel D ^a,d   Sassene, Philip ^b   Kleberg, Karen ^b   Calderone, Marilyn ^c   Igonin, Annabel ^d   Jule, Eduardo ^d   Vertommen, Jan ^d   Blundell, Ross ^c   Benameur, Hassan ^d   Müllertz, Anette ^b   Pouton, Colin W ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c SANOFI   (France)

^d CAPSUGEL   (France)

Author keywords

bioavailability; drug solubilization; in vitro digestion testing; in vitro models; LFCS Consortium; lipid based drug delivery systems; precipitation; SEDDS; solubility; supersaturation

Indexed keywords

DANAZOL; FENOFIBRATE; LIPID; LONG CHAIN FATTY ACID; MEDIUM CHAIN FATTY ACID; TOLFENAMIC ACID;

ANALYTICAL PARAMETERS; AQUEOUS SOLUTION; ARTICLE; CHEMICAL PHENOMENA; CONTROLLED STUDY; CRYSTALLIZATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DEGRADATION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY; INTESTINE; MAXIMUM SUPERSATURATION RATIO; PRECIPITATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; SCREENING TEST; STANDARDIZATION; SUPERSATURATION;

CHEMICAL PRECIPITATION; CRYSTALLIZATION; DIGESTION; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; INTESTINES; LIPID METABOLISM; LIPIDS; ORTHO-AMINOBENZOATES; PHARMACEUTICAL VEHICLES; SOLUBILITY;

EID: 84890549371     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1038-z     Document Type: Article

References (56)

1. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-48.
2. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65:315-499.
3. Hauss DJ. Enhancing the bioavailability of poorly water-soluble drugs. New York: Informa Healthcare; 2007.
4. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9:87-93.
5. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004;21:1405-12.
6. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60:673-91.
7. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 2007;96:235-48.
8. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther. 1998;284:362-9.
9. Goole J, Lindley DJ, Roth W, Carl SM, Amighi K, Kauffmann JM, et al. The effects of excipients on transporter mediated absorption. Int J Pharm. 2010;393:17-31.
10. Trevaskis NL, Porter CJH, Charman WN. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab Dispos. 2006;34:729-33.
11. Patel JP, Brocks DR. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol. 2009;5:1385-98.
12. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60:702-16.
13. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. [Review] [85 refs]. Eur J Pharm Sci. 2002;15:405-15.
14. Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, et al. Lipid digestion as a trigger for supersaturation: in vitro and in vivo evaluation of the utility of polymeric precipitation inhibitors in self emulsifying drug delivery systems. Mol Pharm. 2012;9:2063-79.
15. Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, et al. Characterization and optimization of AMG 517 Supersaturatable Self-Emulsifying Drug Delivery System (S-SEDDS) for improved oral absorption. J Pharm Sci. 2009;98:516-28.
16. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98:2549-72.
17. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278-87.
18. Yeap YY, Trevaskis NL, Quach T, Tso P, Charman WN, and Porter CJH. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. Mol Pharmaceut. 2013. doi: 10.1021/mp3006566
19. Yeap YY, Trevaskis NL, and Porter CJH. The acidic microclimate of the intestinal unstirred water layer can promote drug absorption from long-chain mixed micelles via induction of supersaturation at the absorptive site. Pharm Res. This issue:2013.
20. Williams HD, Anby MU, Sassene P, Kleberg K, Bakala N'Goma JC, Calderone M, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations: 2) The effect of bile salt concentration and drug loading on the performance of Type I, II, IIIA, IIIB and IV formulations during in vitro digestion. Mol Pharm. 2012;9:3286-300.
21. James PF. Kinetics of crystal nucleation in silicate-glasses. J Non-Cryst Solids. 1985;73:517-40.
22. Turnbull D, Fischer JC. Rate of nucleation in condensed systems. J Chem Phys. 1949;17:71-3.
23. Cuine JF, Charman WN, Pouton CW, Edwards GA, Porter CJH. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm Res. 2007;24:748-57.
24. Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res. 2006;23:2165-74.
25. Williams HD, Sassene P, Kleberg K, Bakala N'Goma JC, Calderone M, Jannin V, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations: 1) Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci. 2012;101:3360-80.
26. Sassene P, Kleberg K, Williams HD, Bakala N'Goma JC, Calderone M, Jannin V, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations: 3) Effect of calcium and pancreatin concentration. In preparation 2013.
27. Van Speybroeck M, Mellaerts R, Mols R, Do Thi T, Martens JA, Van Humbeeck J, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. 2010;41:623-30.
28. Munoz A, Guichard JP, Reginault P. Micronized fenofibrate. Atherosclerosis. 1994;110:S45-8.
29. Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations. Eur J Pharm Biopharm. 2008;68:283-8.
30. Bergstroem CAS, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem. 2007;50:5858-62.
31. Osterberg T, Svensson M, Lundahl P. Chromatographic retention of drug molecules on immobilised liposomes prepared from egg phospholipids and from chemically pure phospholipids. Eur J Pharm Sci. 2001;12:427-39.
32. Fagerberg JH, Al-Tikriti Y, Ragnarsson G, Bergstrom CAS. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid. Mol Pharm. 2012;9:1942-52.
33. Heinz A, Gordon KC, McGoverin CM, Rades T, Strachan CJ. Understanding the solid-state forms of fenofibrate - A spectroscopic and computational study. Eur J Pharm Biopharm. 2009;71:100-8.
34. Mattei A, Li T. Polymorph formation and nucleation mechanism of tolfenamic acid in solution: an investigation of pre-nucleation solute association. Pharm Res. 2012;29:460-70.
35. Anderson KV, Larsen S, Alhede B, Gelting N, Buchardt O. Characterization of two polymorphic forms of tolfenamic acid, N-(2-Methyl-3-chlorophenyl) anthranilic acid: their crystal structures and relative stabilities. J Chem Soc Perkin Trans. 1989;2:1443-7.
36. Thybo P, Kristensen J, Hovgaard L. Characterization and physical stability of tolfenamic Acid-PVP K30 solid dispersions. Pharm Dev Technol. 2007;12:43-53.
37. Surov AO, Szterner P, Zielenkiewicz W, Perlovich GL. Thermodynamic and structural study of tolfenamic acid polymorphs. J Pharm Biomed Anal. 2009;50:831-40.
38. Arnold YE, Imanidis G, Kuentz M. Study of drug concentration effects on in vitro lipolysis kinetics in medium-chain triglycerides by considering oil viscosity and surface tension. Eur J Pharm Sci. 2011;44:351-8.
39. Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci. 2005;94:929-39.
40. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals, Part 3: is maximum solubility advantage experimentally attainable and sustainable? J Pharm Sci. 2011;100:4349-56.
41. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, et al. Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. J Pharm Sci. 2010;99:4982-91.
42. Kossena GA, Boyd BJ, Porter CJH, Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J Pharm Sci. 2003;92:634-48.
43. Sek L, Porter CJH, Kaukonen AM, Charman WN. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol. 2002;54:29-41.
44. Porter CJH, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA, et al. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J Pharm Sci. 2004;93:1110-21.
45. Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99:3787-806.
46. Mahlin D, Ponnambalam S, Hockerfelt MH, Bergstrom CAS. Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development. Mol Pharm. 2011;8:498-506.
47. Devraj R, Williams HD, Warren DB, Porter CJH, and Pouton CW. Effect of different nonionic surfactants in self-emulsifying lipid formulations on supersaturation during in vitro digestion. Submitted, 2013.
48. Williams HD, Pouton CW, and Porter CJH. Lipid-based formulations and drug supersaturation: Harnessing the unique benefits of the lipid digestion/absorption pathway. Pharm Res. This issue:2013.
49. Bevernage J, Brouwers J, Annaert P, Augustijns P. Drug precipitation-permeation interplay: supersaturation in an absorptive environment. Eur J Pharm Biopharm. 2012;82:424-8.
50. Bevernage J, Brouwers J, Brewster ME, and Augustijns P. Evaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issues. Int J Pharm. 2012. doi: 10.1016/j.ijpharm.2012.11.026
51. Judge RA, Johns MR, White ET. Protein-purification by bulk crystallization - The recovery of ovalbumin. Biotechnol Bioeng. 1995;48:316-23.
52. Vekilov PG. Nucleation. Cryst Growth Des. 2010;10:5007-19.
53. Kashchiev D, von Rosmalen GM. Review: nucleation in solutions revisited. Cryst Res Technol. 2003;38:555-74.
54. Williams HD, Hergaden B, and Porter CJH. Drug supersaturation in digested lipid-based drug delivery systems. AAPS J. S2:2012.
55. Alonzo DE, Raina S, Zhou D, Gao Y, Zhang GGZ, Taylor LS. Characterizing the impact of hydroxypropylmethyl cellulose on the growth and nucleation kinetics of felodipine from supersaturated solutions. Cryst Growth Des. 2012;12:1538-47.
56. Ilevbare GA, Liu H, Edgar KJ, Taylor LS. Inhibition of solution crystal growth of ritonavir by cellulose polymers - factors influencing polymer effectiveness. Cryst Eng Comm. 2012;14:6503-14.